Abstract. Numerous studies have demonstrated that resveratrol has a potential use in cancer prevention and treatment. However, the effects of resveratrol on cancer cell motility and invasiveness remain unclear. The current study aimed to examine the effects of resveratrol on cell migration and invasion in human glioblastoma cells, and to explore the underlying molecular mechanisms. In wound-healing and Matrigel transwell assays, resveratrol was found to significantly inhibit the migration and invasion of U87MG, T98G and U251 glioblastoma cells in vitro. Results from western blot analysis and gelatin zymography revealed that resveratrol also suppressed the expression and activity of matrix metalloproteinase 2 (MMP-2; P<0.05), an important mediator of cell migration and invasion. Furthermore, using a pull-down assay, increased activation of RhoA was observed in glioblastoma cells treated with resveratrol vs. controls (P<0.05). Notably, inhibition of the RhoA/Rho-associated kinase (ROCK) pathway by C3 transferase or Y-27362 was found to attenuate the resveratrol-induced reductions in cell migration and invasion (P<0.05), and also partially rescued the decreased expression and activity of MMP-2 induced by resveratrol (P<0.05). Taken together, the results suggest that resveratrol may inhibit glioblastoma cell motility and invasiveness via activating the RhoA/ROCK signaling pathway.
IntroductionGlioblastoma is the most common and lethal intracranial malignant tumor with a yearly incidence of 3-4 per 100,000 (1). Despite the use of multimodal treatments, the prognosis of glioblastoma has been little improved, with a typical median survival time of only 12-15 months (2). Due to the diffuse infiltration of glioblastoma cells into the brain tissues, resection of the bulk tumor is typically followed by tumor reinitiation at the resection site or at another location in the brain. The highly aggressive and invasive properties of glioblastoma cells contribute significantly to the poor prognosis of cases involving this type of tumor (3). Therefore, it has been proposed that anti-invasion agents may play a crucial role in the treatment of glioblastoma (4).The invasion of malignant cancer cells is favored by degradation of the extracellular matrix (ECM), upregulation of proteolytic enzyme activity and an increase in tumor cell motility and invasive ability (5,6). Accumulating evidence has suggested that matrix metalloproteinases (MMPs) are capable of promoting tumor invasion and metastasis via degradation of the ECM (7), among which two gelatinases, MMP-2 and MMP-9, have attracted the most attention (8). Rho GTPases are a family of small GTP-binding proteins that serve as molecular switches in a wide variety of cellular signaling pathways, ultimately inducing changes in the organization of the actin cytoskeleton and regulating cell motility (9). It has been reported that RhoA activity is significantly reduced in astrocytic tumors (10-12), and increased RhoA activity in glioblastoma cells has been associated with impaired cell mi...